The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Ingelvac CircoFLEX exceed the risks for the active immunisation of pigs, over the age of two weeks, against PCV2, and recommended that Ingelvac CircoFLEX be given a marketing authorisation.